| Income Statement | 2026-02-28 | 2025-11-30 | 2025-08-31 | |
|---|---|---|---|---|
| General and administrative | 1,654 | 1,799 | 1,713 | |
| Research and development | 4,649 | 3,302 | 3,232 | |
| Legal settlement loss | NaN | 16,587 | NaN | |
| Total operating expenses | 6,303 | 21,688 | 4,945 | |
| Operating (loss) gain | -6,303 | -21,688 | -4,945 | |
| Interest income | 15 | 57 | 94 | |
| Interest on convertible notes | 614 | 644 | 676 | |
| Issuance costs for private placement of shares and warrants through placement agent (note 5) | 1,628 | NaN | NaN | |
| Standby equity purchase agreement commitment fee | NaN | 325 | NaN | |
| Legal settlement revaluation | 3,842 | NaN | NaN | |
| Finance charges | 2 | 7 | 13 | |
| Total interest and other expenses | 1,613 | -919 | -595 | |
| (loss) gain before income taxes | -4,690 | -22,607 | -5,540 | |
| Income tax benefit | 0 | 0 | 0 | |
| Net (loss) income | -4,690 | -22,607 | -5,540 | |
| Basic EPS | 0 | -0.02 | 0 | |
| Diluted EPS | 0 | -0.02 | 0 | |
| Basic Average Shares | 1,275,184,000 | 1,261,016,000 | 1,252,551,000 | |
| Diluted Average Shares | 1,275,184,000 | 1,261,016,000 | 1,252,551,000 | |
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)